Antibodies against cd73 and uses thereof

A method of decreasing adenosine levels in a tumor of a human subject, comprising administering to the subject an antibody, or antigen binding portion thereof, that binds to human CD73, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:

• 5, 6, and 7, respectively, and a light chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:
• 13, 14, and 15, respectively.

A method of stimulating an immune response against a tumor in a human subject in need thereof, comprising administering to the subject an effective amount of an antibody, or antigen binding portion thereof, that binds to human CD73, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:

• 5, 6, and 7, respectively, and a light chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:
• 13, 14, and 15, respectively.

A method of stimulating an immune response in a human subject comprising administering to the subject an antibody, or antigen binding portion thereof, that binds to CD73, to the subject, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:

• 5, 6, and 7, respectively, and a light chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:
• 13, 14, and 15, respectively.

A method for inhibiting the growth of a tumor in a human subject comprising administering to the subject an antibody, or antigen binding portion thereof, that binds to human CD73, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:

• 5, 6, and 7, respectively, and a light chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:
• 13, 14, and 15, respectively.

A method of treating cancer in a human subject, comprising administering to the subject a therapeutically effective amount of an antibody, or antigen binding portion thereof, that binds to human CD73, to the subject, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:

• 5, 6, and 7, respectively, and a light chain comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs:
• 13, 14, and 15, respectively.